致：香港交易及結算所有限公司 公司名稱: 萬嘉集團控股有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00401 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 0.05 | HKD | | 50,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 1,000,000,000 | HKD | | 0.05 | HKD | | 50,000,000 | 本月底法 ...

Group 1 - The core point of the article is that Wanjia Group's subsidiary, Wuhua Yangke, has received a notice from the Wuhua County Medical Security Management Center regarding violations in prescription management and related regulations [1] - The notice indicates that Wuhua Yangke's blood dialysis center has deviated from standard medical prescription practices, leading to regulatory breaches [1] - As a result of these violations, the Wuhua Medical Security Management Center has implemented measures against Wuhua Yangke [1] Group 2 - As of October 28, 2025, Wanjia Group's stock closed at HKD 0.13, down 4.32%, with a trading volume of 39,600 shares and a turnover of HKD 5,075 [1] - The company has a market capitalization of HKD 77.87 million, ranking 9th in the pharmaceutical commercial sector [1] - Key financial metrics for Wanjia Group include a Return on Equity (ROE) of -37.38%, revenue of HKD 171 million, and a net profit margin of 1.58% [1]

Core Viewpoint - Wanjia Group's subsidiary, Wuhua Yangke, has received a notice from the Wuhua County Medical Security Management Center regarding non-compliance in its blood dialysis center operations, leading to a suspension of its service agreement for 61 days starting November 1, 2025 [1][2]. Group 1 - Wuhua Yangke's blood dialysis center was found to have deviated from standard medical prescription practices, violating relevant regulations [1]. - The management and legal representatives of Wuhua Yangke are required to attend a meeting with the Wuhua Medical Security Management Center to address the non-compliance issues [1]. - The service agreement with the Wuhua Medical Security Management Center will be suspended for 61 days, starting from November 1, 2025 [1]. Group 2 - During the suspension period, the Wuhua blood dialysis center will continue to operate but will not provide any services covered under the suspended agreement [2]. - Existing patients will be redirected to nearby dialysis centers or hospitals during the suspension [2]. - The company has confirmed that there are no similar non-compliance issues in its other dialysis centers and is implementing corrective measures to prevent future occurrences [2].

Core Viewpoint - Wanjia Group's subsidiary, Wuhua Yangke Kidney Dialysis Co., has received a notice from the Wuhua County Medical Security Management Center regarding non-compliance with medical prescription regulations, leading to a suspension of its service agreement for 61 days starting November 1, 2025 [1][2] Group 1 - Wuhua Yangke's dialysis center was found to have deviated from standard medical prescription practices, violating multiple regulations including the Prescription Management Measures and the Drug Administration Law of China [1] - The Wuhua Medical Security Management Center has mandated that the legal representative and management of Wuhua Yangke attend a meeting to address the non-compliance issues [1] - The service agreement with the Wuhua Medical Security Management Center will be suspended for 61 days, during which the dialysis center will not provide any services covered under the agreement [1][2] Group 2 - The company is taking the non-compliance issues seriously and will implement immediate corrective measures, including a comprehensive internal control review of the dialysis center's operations [2] - During the suspension period, the dialysis center will continue to operate but will only offer services outside the scope of the suspended agreement, with existing patients being redirected to nearby facilities [2] - The company believes that the limited operations during the suspension will not have a significant adverse impact on its financial condition, business, or daily operations [2]

Core Viewpoint - Wan Jia Group's subsidiary, Wuhua Yangke, has received a notice from the Wuhua County Medical Security Management Center regarding non-compliance in prescription practices, leading to a suspension of its service agreement for 61 days starting November 1, 2025 [1][2] Group 1 - Wuhua Yangke's blood dialysis center deviated from standard medical prescription practices, violating regulations [1] - The management and legal representative of Wuhua Yangke are required to attend a meeting with the Wuhua Medical Security Management Center to address the non-compliance issues [1] - The service agreement with the Wuhua Medical Security Management Center will be suspended for 61 days, starting from November 1, 2025 [1] Group 2 - The company is taking the non-compliance issues seriously and will implement corrective measures, including a comprehensive internal control review of the dialysis center's operations [2] - During the suspension period, the dialysis center will continue to operate but will not provide any services covered under the suspended agreement [2] - The company believes that the limited operations during the suspension will not have a significant adverse impact on its financial condition or daily operations [2]

WANJIA GROUP HOLDINGS LIMITED 萬嘉集團控股有限公 司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈 全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 （於開曼群島註冊成立之有限公司） （股份代號：401) 自願公佈 本公佈乃由萬嘉集團控股有限公司（「本公司」，連同其附屬公司統稱「本集 團」）自願作出。 本公司宣佈，本公司間接非全資附屬公司五華養可腎析血液透析有限公司 （「五華養可」）近期收到五華縣醫療保障事業管理中心（「五華醫保管理中心」） 於二零二五年十月二十三日發出的協議處理告知書（「告知書」）。根據告知書， 由於五華養可經營的血液透析治療中心（「五華血液透析中心」）偏離常規醫藥 處方開方情況，導致違反處方管理辦法、中華人民共和國（「中國」）藥品管理法 及梅州市定點醫療機構醫療保障服務協議書（「保障服務協議書」）的規定。五 華醫保管理中心因此已對五華養可採取以下措施： 1. 五華養可的法定代表人及管理層須出席五華醫保管理中心的約談，並對 相關不合規事項進行整改；及 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈 全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 萬嘉集團控股有限公 司 （於開曼群島註冊成立之有限公司） （股份代號：401) 於二零二五年九月五日舉行之股東週年大會之投票結果 董事會欣然宣佈，股東週年大會通告所載之所有決議案已於股東週年大會 上以投票表決方式獲股東正式通過。 萬嘉集團控股有限公司（「本公司」）董事（「董事」）會（「董事會」）欣然宣佈，日 期為二零二五年七月三十一日之股東週年大會（「股東週年大會」）通告（「該通 告」）所詳載之所有決議案已以投票表決方式獲出席於二零二五年九月五日舉 行之股東週年大會並於會上投票之本公司股東（「股東」）正式通過。本公司之 香港股份過戶登記分處卓佳證券登記有限公司獲委任為於股東週年大會上點 票之監票人。 於股東週年大會日期，本公司之已發行股份總數為560,222,136股普通股，即賦 予其持有人權利出席並可就所有決議案投票之股份總數。概無股東須根據上 市規則於股東週年大會上就任何決議案放棄投票，亦無股東根據 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 萬嘉集團控股有限公司 呈交日期: 2025年9月1日 本月底法定/註冊股本總額： HKD 50,000,000 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00401 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 0.05 | HKD | | 50,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 1,000,000,000 | HKD | | 0.05 ...

Summary of Key Points Core Viewpoint - A total of 142 stocks reached their 52-week highs as of August 12, with notable performers including Yingmei Holdings (02028), Elite Group (01775), and Fuying Global Group (01620) achieving high rates of 164.89%, 84.78%, and 40.63% respectively [1]. Stock Performance - **Top Performers**: - Yingmei Holdings (02028) closed at 0.223 with a peak of 0.249, marking a 164.89% increase [1]. - Elite Group (01775) closed at 0.350 with a peak of 0.425, reflecting an 84.78% increase [1]. - Fuying Global Group (01620) closed at 0.180, reaching its peak at 0.180, showing a 40.63% increase [1]. - **Other Notable Stocks**: - Aoya Group (02425) increased by 34.36% [1]. - Fuyiy International Holdings (01470) saw a rise of 28.30% [1]. - Huajian Medical (01931) experienced a 27.58% increase [1]. 52-Week High Rankings - The ranking of stocks that reached their 52-week highs includes: - Yingmei Holdings (02028) at 164.89% [1]. - Elite Group (01775) at 84.78% [1]. - Fuying Global Group (01620) at 40.63% [1]. 52-Week Low Rankings - The report also highlights stocks that reached their 52-week lows, with notable declines including: - Jiadeng International Group (08153) at -15.25% [4]. - Kun Group (00924) at -12.86% [4]. - Zhongjia Guoxin (00899) at -10.00% [4].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 萬嘉集團控股有限公司 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00401 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 0.05 | HKD | | 50,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 1,000,000,000 | HKD | | 0.05 | HKD | | 50,000,000 | 本月底法定/註冊股本總額： HKD 50,000,000 FF301 ...